CREB-TARGET GENES IN MALIGNANT MESOTHELIOMA

恶性间皮瘤中的 CREB ​​靶基因

基本信息

  • 批准号:
    7959898
  • 负责人:
  • 金额:
    $ 0.68万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2009
  • 资助国家:
    美国
  • 起止时间:
    2009-07-01 至 2010-06-30
  • 项目状态:
    已结题

项目摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Malignant mesotheliomas (MMs) are aggressive neoplasms that are derived from the surface serosal cells of the pleural and peritoneal cavities. MM is associated with asbestos exposure however, little is known about the crucial cellular mechanisms contributing to the development and chemoresistance of MM. cAMP response element binding protein (CREB) is a transcription factor that rgulates a variety of cellular functions. CREB-dependent gene expression is also linked to various functions like growth/survival, migration/invasion, angiogenesis and drug resistance. The role of CREB has been studied in a few cancers but its role in MM is completely unknown. Data from our laboratory show increased activation of CREB and CREB-regulated genes in human mesothelial cells after asbestos exposure as well increased endogenous activation of CREB in 5 human MM lines and in tissue arrays from 3 MM patients. We hypothesized that CREB activation leads to expression of CREB-regulated genes involved in various tumorigenesis and drug resistance process of MM. In the present proposal we studied by microarray analysis (U133A2 Affymetrix chip and GeneSifter program to analyze data) common CREB-regulated genes after transfecting two different MM cell lines (Hmeso and PPMMill) with sh CREB or negative control. This study revealed a set of CREB-regulated genes involved in various tumorigenec processes in Hmeso (167 increased and 279 decreased more than 2 fold) and PPMMill (1555 increased and 2144 decreased more than 2 fold) mesothelioma cell lines. Functional relevance of identified genes in two MM cell lines will be validated and explored in a larger study. Identified genes could possibly act as potential target for MM treatment either alone or in combination with chemotherapeutic drugs.
这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者(PI)可能从另一个NIH来源获得了主要资金, 因此可以在其他CRISP条目中表示。所列机构为 研究中心,而研究中心不一定是研究者所在的机构。 恶性间皮瘤(malignant mesotheliomas,简称MM)是一种侵袭性肿瘤,起源于胸膜腔和腹膜腔的表面浆膜细胞。MM与石棉接触有关,但对MM发生和耐药的关键细胞机制知之甚少。cAMP反应元件结合蛋白(CREB)是一种调节多种细胞功能的转录因子。CREB依赖性基因表达还与各种功能如生长/存活、迁移/侵袭、血管生成和耐药性相关。CREB的作用已经在一些癌症中进行了研究,但其在MM中的作用完全未知。我们实验室的数据显示,暴露于石棉后,CREB和CREB调节基因在人间皮细胞中的活化增加,以及CREB在5个人MM细胞系和3个MM患者的组织阵列中的内源性活化增加。我们假设CREB激活导致CREB调节基因的表达,这些基因参与MM的各种肿瘤发生和耐药过程。在本提议中,我们通过微阵列分析(U133 A2 Affyellow芯片和GeneSifter程序来分析数据)研究了两种不同的MM细胞系(Hmeso和PPMMill)与sh CREB或阴性对照一起转染后的共同CREB调节基因。这项研究揭示了一组CREB调节基因参与Hmeso(167增加和279减少超过2倍)和PPMMill(1555增加和2144减少超过2倍)间皮瘤细胞系中的各种致瘤过程。将在一项更大规模的研究中验证和探索两种MM细胞系中已鉴定基因的功能相关性。已识别的基因可能单独或与化疗药物联合作为MM治疗的潜在靶点。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

ARTI SHUKLA其他文献

ARTI SHUKLA的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('ARTI SHUKLA', 18)}}的其他基金

Inflammasomes in pathogenesis of mesothelioma
间皮瘤发病机制中的炎症小体
  • 批准号:
    8764721
  • 财政年份:
    2012
  • 资助金额:
    $ 0.68万
  • 项目类别:
Inflammasomes in pathogenesis of mesothelioma
间皮瘤发病机制中的炎症小体
  • 批准号:
    8411134
  • 财政年份:
    2012
  • 资助金额:
    $ 0.68万
  • 项目类别:
Inflammasomes in pathogenesis of mesothelioma
间皮瘤发病机制中的炎症小体
  • 批准号:
    8573591
  • 财政年份:
    2012
  • 资助金额:
    $ 0.68万
  • 项目类别:
Inflammasomes in pathogenesis of mesothelioma
间皮瘤发病机制中的炎症小体
  • 批准号:
    8217648
  • 财政年份:
    2012
  • 资助金额:
    $ 0.68万
  • 项目类别:

相似海外基金

Establishment of a Mouse NK Cell Line for Analyzing Tumor Infiltration Processes and Developing a Preclinical Model for Cancer Immunotherapy.
建立小鼠 NK 细胞系,用于分析肿瘤浸润过程并开发癌症免疫治疗的临床前模型。
  • 批准号:
    23K06731
  • 财政年份:
    2023
  • 资助金额:
    $ 0.68万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Proof of usefulness of PDX derived cell line
PDX 衍生细胞系的有用性证明
  • 批准号:
    23K06616
  • 财政年份:
    2023
  • 资助金额:
    $ 0.68万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
A novel producer cell line for more efficient manufacturing of viral vector systems
用于更有效地制造病毒载体系统的新型生产细胞系
  • 批准号:
    10597799
  • 财政年份:
    2023
  • 资助金额:
    $ 0.68万
  • 项目类别:
Genestorian: a web application to document and trace genetic modifications in model organism and cell line collections.
Genestorian:一个网络应用程序,用于记录和追踪模型生物和细胞系集合中的遗传修饰。
  • 批准号:
    EP/Y024591/1
  • 财政年份:
    2023
  • 资助金额:
    $ 0.68万
  • 项目类别:
    Fellowship
AI-Aided Tool for Day Zero Selection of High Performing Cells for Biopharma Cell Line Development
用于生物制药细胞系开发的高性能细胞零日选择的人工智能辅助工具
  • 批准号:
    10672364
  • 财政年份:
    2022
  • 资助金额:
    $ 0.68万
  • 项目类别:
Developing a stable cell line expressing recombinant sclerostin
开发表达重组硬化素的稳定细胞系
  • 批准号:
    10385037
  • 财政年份:
    2022
  • 资助金额:
    $ 0.68万
  • 项目类别:
Development of Natural Killer (NK) Cell Line-Derived Extracellular Vesicles as a New Treatment for Cancer
开发自然杀伤 (NK) 细胞系衍生的细胞外囊泡作为癌症的新治疗方法
  • 批准号:
    10383462
  • 财政年份:
    2022
  • 资助金额:
    $ 0.68万
  • 项目类别:
A cell culture management platform to improve biomedical reproducibility by combining cell line tracking, low-cost genetic analysis, and riskassessment
细胞培养管理平台,通过结合细胞系追踪、低成本遗传分析和风险评估来提高生物医学重现性
  • 批准号:
    10483063
  • 财政年份:
    2022
  • 资助金额:
    $ 0.68万
  • 项目类别:
AI-Aided Tool for Day Zero Selection of High Performing Cells for Biopharma Cell Line Development
用于生物制药细胞系开发的高性能细胞零日选择的人工智能辅助工具
  • 批准号:
    10546865
  • 财政年份:
    2022
  • 资助金额:
    $ 0.68万
  • 项目类别:
Modulating expression of candidate genes to improve lentiviral vector production in stable cell line
调节候选基因的表达以提高稳定细胞系中慢病毒载体的产量
  • 批准号:
    2752732
  • 财政年份:
    2022
  • 资助金额:
    $ 0.68万
  • 项目类别:
    Studentship
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了